Kirsten rat sarcoma (KRAS) mutations are the most frequent oncogenic driver alterations in NSCLC, detectable in up to 30% of cases in Caucasian patients, with much lower rates in patients of Asian descent [62]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.